FDA Enforcement Now Includes Medically Integrated Dispensaries
What changed: The Drug Supply Chain Security Act (DSCSA) is now being enforced at the medical practice level. Any practice that purchases, stores, or dispenses drug products in-office is subject to FDA supply chain compliance inspections not just manufacturers, wholesale distributors, and retail pharmacies. MIDs sit squarely in the FDA’s definition of a dispenser, and enforcement has arrived.
The Drug Products at Issue in Medically Integrated Dispensaries
If your practice purchases and dispenses any of the following to patients, federal drug supply chain requirements apply regardless of specialty or practice model:
ONCOLOGY & INFUSION THERAPIES
• Monoclonal antibodies (Herceptin, Avastin, Keytruda, Opdivo)
• Biosimilars any FDA-approved biosimilar to a reference biologic
• Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab)
• Supportive agents (filgrastim, epoetin alfa, darbepoetin)
• Iron infusion products (Injectafer, Venofer, Monoferric)
• IV immunoglobulin (IVIG Gamunex, Privigen, Octagam)
RHEUMATOLOGY & SPECIALTY INJECTABLES
• Biologics (Humira, Enbrel, Remicade, Simponi, Orencia)
• IL-6 inhibitors (Actemra, Kevzara)
• JAK inhibitors dispensed in-office
• Corticosteroids (methylprednisolone, triamcinolone)
• Hyaluronic acid joint injections (Synvisc, Euflexxa, Monovisc)
• Denosumab (Prolia, Xgeva) bone health biologics
NEUROLOGY, UROLOGY & OTHER SPECIALTY
• MS therapies (Ocrevus, Tysabri, Lemtrada infused)
• Enzyme replacement therapies (Fabrazyme, Myozyme, Cerezyme)
• Botulinum toxin (Botox therapeutic indications)
• Ketamine infusions (compounded and branded)
• Testosterone and hormone injectables
WEIGHT MANAGEMENT & EMERGING DISPENSARY PRODUCTS
• GLP-1 agonists (semaglutide, tirzepatide branded and compounded)
• Peptide therapies (BPC-157, Ipamorelin, Sermorelin, CJC-1295)
• NAD+ infusions and compounded IV therapies
• Vitamin and nutrient IV infusions with Rx components
• Compounded products from 503A/503B facilities
